<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39035011</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Autoantibodies in COVID-19 survivors with post-COVID symptoms: a systematic review.</ArticleTitle><Pagination><StartPage>1428645</StartPage><MedlinePgn>1428645</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1428645</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1428645</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The long-lasting persistence of autoantibodies stands as one of the hypotheses explaining the multisystemic manifestations seen in individuals with post-COVID-19 condition. The current review offers restricted insights into the persistence of autoantibodies in plasma/serum in people with post-COVID symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">PubMed/MEDLINE, CINAHL, EMBASE, and Web of Science databases, as well as on medRxiv and bioRxiv preprint servers were searched up to January 5<sup>th</sup>, 2024. Papers investigating the presence of autoantibodies in plasma/serum samples in people with post-COVID symptoms were included. The Newcastle-Ottawa Scale (NOS) was used to assess methodological quality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">From 162 identified records, five articles met all inclusion criteria; four studies included infected controls with no post-COVID symptoms whereas all five studies included non-infected controls (410 COVID-19 survivors with post-COVID symptoms, 223 COVID-19 survivors with no post-COVID symptoms as controls and 266 non-infected healthy controls). Four studies concluded that the presence of autoantibodies had a potential (but small) role in post-COVID-19 condition whereas one study concluded that autoantibodies were not associated. Quality assessment showed all studies had high methodological quality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Although evidence suggests that persistent autoantibodies can be associated with post-COVID symptoms, the clinical relevance of their presence seems modest at this stage. Current results highlight further research to clarify the role of autoantibodies in the development of post-COVID symptoms, guiding the development of tailored diagnostic and treatment approaches to enhance patient outcomes.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">https://osf.io/vqz28.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Notarte, Carandang, Velasco, Pastrana, Ver, Manalo, Ng, Grecia, Lippi, Henry and Fern&#xe1;ndez-de-las-Pe&#xf1;as.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Notarte</LastName><ForeName>Kin Israel</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carandang</LastName><ForeName>Timothy Hudson David Culasino</ForeName><Initials>THDC</Initials><AffiliationInfo><Affiliation>Pamantasan ng Lungsod ng Maynila College of Medicine, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Jacqueline Veronica</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cardinal Santos Medical Center, San Juan, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastrana</LastName><ForeName>Adriel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ver</LastName><ForeName>Abbygail Therese</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manalo</LastName><ForeName>Gerald Neil</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Jeremy Ace</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>College of Medicine, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grecia</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lippi</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Section of Clinical Biochemistry, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Brandon Michael</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Madrid, OH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-de-Las-Pe&#xf1;as</LastName><ForeName>C&#xe9;sar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="Y">Survivors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection (COVID-19)</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39035011</ArticleId><ArticleId IdType="pmc">PMC11257835</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1428645</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization . COVID-19 Epidemiological Update &#x2013; 22 December 2023 (2023). Available online at: https://www.who.int/publications/m/item/covid-19-epidemiological-update&#x2014;22-december-2023.</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. (2022) 22:e102&#x2013;7. doi:&#xa0;10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. . Development of a definition of postacute sequelae of SARS-coV-2 infection. JAMA. (2023) 329:1934. doi:&#xa0;10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023) 21:133&#x2013;46. doi:&#xa0;10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-las-Pe&#xf1;as C, Notarte KI, Macasaet R, Velasco JV, Catahay JA, Ver AT, et al. . Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis. J Infection. (2024) 88:77&#x2013;88. doi:&#xa0;10.1016/j.jinf.2023.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.12.004</ArticleId><ArticleId IdType="pubmed">38101521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G, Townsend L, Savinelli S, Mallon PWG. Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets. Front Mol Biosci. (2023) 10:1157651. doi:&#xa0;10.3389/fmolb.2023.1157651</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2023.1157651</ArticleId><ArticleId IdType="pmc">PMC10171433</ArticleId><ArticleId IdType="pubmed">37179568</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x2019;Huillier AG, Pagano S, Baggio S, Meyer B, Andrey DO, Nehme M, et al. . Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence. Eur J Clin Invest. (2022) 52:e13818. doi:&#xa0;10.1111/eci.13818</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13818</ArticleId><ArticleId IdType="pmc">PMC9348059</ArticleId><ArticleId IdType="pubmed">35598178</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, et al. . Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. Eur Respir J. (2022) 61:2200970. doi:&#xa0;10.1183/13993003.00970-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00970-2022</ArticleId><ArticleId IdType="pmc">PMC9515477</ArticleId><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes S-S, et al. . The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. (2022) 3:100663. doi:&#xa0;10.1016/j.xcrm.2022.100663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibert FS, Stervbo U, Wiemers L, Skrzypczyk S, Hogeweg M, Bertram S, et al. . Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. Autoimmun Rev. (2023) 22:103445. doi:&#xa0;10.1016/j.autrev.2023.103445</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2023.103445</ArticleId><ArticleId IdType="pubmed">37689093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarini MR, Bonetti G, Medori MC, Dhuli K, Tezzele S, Micheletti C, et al. . Autoantibodies in patients with post-COVID syndrome: a possible link with severity? Eur Rev Med Pharmacol Sci. (2023) 27:48&#x2013;56. doi:&#xa0;10.26355/eurrev_202312_34689</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202312_34689</ArticleId><ArticleId IdType="pubmed">38112956</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari A, Hadizadeh A, Islampanah M, Salavati Nik E, Atkin SL, Sahebkar A. COVID-19, G protein-coupled receptor, and renin-angiotensin system autoantibodies: Systematic review and meta-analysis. Autoimmun Rev. (2023) 22:103402. doi:&#xa0;10.1016/j.autrev.2023.103402</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2023.103402</ArticleId><ArticleId IdType="pubmed">37490975</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolska K, Zar&#x119;bska-Michaluk D, Poniedzia&#x142;ek B, Jaroszewicz J, Flisiak R, Rzymski P. Overview of autoantibodies in COVID-19 convalescents. J Med Virol. (2023) 95:e28864. doi:&#xa0;10.1002/jmv.28864</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28864</ArticleId><ArticleId IdType="pubmed">37310140</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. doi:&#xa0;10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wells G, Shea B, O&#x2019;Connell D, Peterson J, Welch V, Losos M, et al. . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available online at: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.</Citation></Reference><Reference><Citation>Geanes ES, McLennan R, LeMaster C, Bradley T. Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity. Commun Med. (2024) 4(1):47. doi:&#xa0;10.1038/s43856-024-00477-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-024-00477-z</ArticleId><ArticleId IdType="pmc">PMC10943194</ArticleId><ArticleId IdType="pubmed">38491326</ArticleId></ArticleIdList></Reference><Reference><Citation>Alphan Uc Z, Yagc&#x131; P, Adibelli Z, Duran C. The spectrum of thyroid function tests and autoantibodies during hospitalization and after six months of discharge in COVID-19 patients: does COVID-19 trigger autoimmunity? Endocrine Res. (2023) 48:44&#x2013;54. doi:&#xa0;10.1080/07435800.2023.2188086</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07435800.2023.2188086</ArticleId><ArticleId IdType="pubmed">36883908</ArticleId></ArticleIdList></Reference><Reference><Citation>Achleitner M, Steenblock C, D&#xe4;nhardt J, Jarzebska N, Kardashi R, Kanczkowski W, et al. . Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Mol Psychiatry. (2023) 28:2872&#x2013;7. doi:&#xa0;10.1038/s41380-023-02084-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-023-02084-1</ArticleId><ArticleId IdType="pmc">PMC10152027</ArticleId><ArticleId IdType="pubmed">37131073</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A, et al. . Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Trans Autoimmun. (2021) 4:100100. doi:&#xa0;10.1016/j.jtauto.2021.100100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Boesl F, Goereci Y, Gerhard A, Schweitzer F, Schroeder M, et al. . Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behavior Immun. (2023) 109:139&#x2013;43. doi:&#xa0;10.1016/j.bbi.2023.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2023.01.006</ArticleId><ArticleId IdType="pmc">PMC9841734</ArticleId><ArticleId IdType="pubmed">36657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Mitchell A, Wang CY, Takahashi S, Hoh R, Tai V, et al. . Low prevalence of interferon &#x3b1; Autoantibodies in people experiencing symptoms of post&#x2013;coronavirus disease 2019 (COVID-19) conditions, or long COVID. J Infect Dis. (2023) 227:246&#x2013;50. doi:&#xa0;10.1093/infdis/jiac372</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac372</ArticleId><ArticleId IdType="pmc">PMC9494362</ArticleId><ArticleId IdType="pubmed">36089700</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. . Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): A prospective cohort study. Clin Infect Dis. (2022) 74:1191&#x2013;8. doi:&#xa0;10.1093/cid/ciab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr&#xed;guez Y, Zapata E, Ram&#xed;rez-Santana C, et al. . Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis. (2022) 225:2155&#x2013;62. doi:&#xa0;10.1093/infdis/jiac017</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, et al. . Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. (2022) 13:981532. doi:&#xa0;10.3389/fimmu.2022.981532</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.981532</ArticleId><ArticleId IdType="pmc">PMC9552223</ArticleId><ArticleId IdType="pubmed">36238301</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>